Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 9/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921791 | 0.90 | PDE2A (0.49) | CACNA2D1MAPTNPC1 | |
| SCHEMBL4927269 | 0.90 | CACNA2D1 (0.48) | CACNA2D1MAPT | |
| SCHEMBL4925569 | 0.89 | MCHR1 (0.48) | CACNA2D1KMT2AEHMT2MAPTHPGD | |
| SCHEMBL4931085 | 0.85 | CACNA2D1 (0.43) | CACNA2D1KMT2AMAPTMEN1NPC1 | |
| SCHEMBL4931125 | 0.85 | CYP19A1 (0.48) | KMT2AMAPTMEN1NPC1HPGD | |
| SCHEMBL4933013 | 0.83 | PDE2A (0.38) | KMT2AMAPTMEN1 | |
| SCHEMBL4933479 | 0.83 | CACNA2D1 (0.45) | CACNA2D1KMT2AEHMT2MAPTALDH1A1 | |
| SCHEMBL4926405 | 0.80 | NPC1 (0.56) | CACNA2D1KMT2AMAPTNPC1HPGD | |
| SCHEMBL4930490 | 0.80 | HTT (0.53) | CACNA2D1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL4925649 | 0.79 | NPC1 (0.55) | CACNA2D1KMT2AMAPTNPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1810677-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021069-A1 | Receptor Function Regulating Agent | GPR119, INSR, GPR65 | CACNA2D1 3298/4885KMT2A 1963/4885EHMT2 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.